Amgen Clarifies Non‑GAAP Restructuring Exclusions

Amgen’s clarification — that restructuring costs are excluded from non‑GAAP measures — is a narrow, technical disclosure about how the company reports adjusted results. Non‑GAAP measures that exclude restructuring expenses will present operating performance net of those one‑time or infrequent charges, which can improve year‑over‑year comparability for underlying business trends but will diverge from GAAP results that include all costs. Investors should view this clarification in the context of Amgen’s single reportable segment (human therapeutics) and its FY2025 scale: total product sales of $35,148 million (U.S. $25,656M; ROW $9,492M). With major products and collaborations across immunology, oncology and rare disease, non‑GAAP adjustments that remove restructuring costs may materially affect headline operating metrics used to evaluate pipeline investment and commercial execution.

Excluding restructuring costs from adjusted performance is consistent with common non‑GAAP practices that isolate recurring operating results from discrete restructuring events. For analysts and modelers, key follow‑ups include whether Amgen provides a reconciliation showing the magnitude and timing of excluded restructuring charges, and whether similar exclusions will apply consistently across quarterly and annual reporting periods. Absent disclosure of new restructuring actions, investors should treat current non‑GAAP presentations as reflecting Amgen’s stated policy on exclusions rather than recent cost‑cutting moves. Any future restructuring — if announced — would change the composition of excluded items and could affect cash flow timing, impairment recognition and adjusted operating margins.

Amgen’s reporting stance sits against a backdrop of legal, regulatory and market pressures documented in company filings: ongoing patent and litigation exposures, pricing and reimbursement shifts, and product‑specific regulatory paths. While the company reported no new restructuring actions, those broader risks remain potential catalysts for future restructuring decisions. Investors should monitor legal outcomes, pricing rules, product approvals and competitive biosimilar pressures as factors that could prompt discrete restructuring activities in coming periods.